This therapy targets two distinct antigen-binding sites involved in immune regulation, representing a pivotal evolution in the treatment landscape for advanced or metastatic NSCLC patients who have progressed after receiving treatment with an epidermal growth factor receptor tyrosine kinase inhibitor and have EGFR gene mutation positivity. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.